Clinical Trials Service

The Division of Allergy & Immunology is conducting new and exciting studies. If you or someone you know is eligible and interested, we would love to hear from you. Please call: (402) 280-5975

Patient Demographics

The Omaha area has a population of over 750,000. The Division’s clinical research patient database alone is currently comprised of over 5,000 patients and is constantly growing through the various recruitment efforts including media advertising, health fair involvement as well as volunteer work. Our diverse patient population is drawn not only from the Omaha metropolitan area (urban/suburban), but also from the surrounding communities in Eastern Nebraska and Western Iowa (rural).

Areas of Research

- Acute and chronic otitis media
- Acute and chronic urticaria
- Acute sinusitis
- Allergic asthma
- Allergic bronchopulmonary aspergillosis
- Allergic conjunctivitis
- Angioedema
- Asthma in pregnancy
- B cell immunodeficiencies
- Bronchitis
- Common variable immunodeficiency
- Contact dermatitis
- Drug allergy
- Exercise induced asthma
- Food allergy and food hypersensitivity
- Immunizations and immunoprophylaxis
Insect allergy
Latex allergy
Management of immunotherapy
Non-allergic asthma
Nasal polyposis
Perennial allergic rhinitis
Seasonal allergic rhinitis
Status asthmaticus
T-cell immunodeficiencies
Vasomotor rhinitis
Urticaria

**Procedures and Equipment Available**

- Acoustic Rhinometry
- Aeroallergen challenge
- Exercise challenge
- Hypertonic Saline challenge
- Methacholine challenge
- Bronchoprovocation Challenges
- Biomarker Assays (Interleukins/Cytokines, Leukotrienes, Histamine, Tryptase, ECP)
- Digital Electrocardiography Machine
- Full Pulmonary Function Laboratory
- Immediate and Delayed Hypersensitivity Skin Testing
- Immunotherapy
- Inpatient Beds
- Nasal Allergen Challenges and Lavage
- Nitric Oxide Measurements (oral/nasal)
- Oral Desensitization
- Parenteral Therapy Facilities
- Phlebotomy
- Pollen Collection
- Radiology Suite for Routine X-Rays, MRIs, CTs, Nuclear Studies
- Remote Data Entry Capabilities
- Spirometry
- Sputum Induction
- Treadmill Exercise Testing

**Investigators**

**Thomas B. Casale, M.D.**
Professor of Medicine and Medical Microbiology & Immunology; Chief, Division of Allergy & Immunology

**Robert G. Townley, M.D.**
Professor of Medicine and Medical Microbiology & Immunology

**Agandra K. Bewtra, M.B.B.S.**
Associate Professor of Medicine & Biomedical Sciences

**Jeffrey R. Stokes, M.D.**
Associate Professor of Medicine, Fellowship Program Director, Fellowship Program

**Russell J. Hopp, D.O.**
Professor of Pediatrics and Medicine; Chief, Division of Pediatric Allergy & Clinical Immunology
Staff

Patrick DeNier: Operations Manager
Tony Romero, MS: Budget, Contracts, & Regulatory Documents
Diane Stormberg, RN, BSN: Head Research Coordinator
Jean Kessler, RN, BSN, CCRC: Research Coordinator
Lori Mahon, RN, BSN, CCRC: Research Coordinator
Janie Misfield, MA, CCRC: Research Coordinator
Jean M. Casale, BS, CMA: Research Coordinator
Anna Secor, MA: Research Coordinator

Current Clinical Trials

▪ Study to Determine the Safety and Efficacy of AMG 317 (antibody to IL-13) in Subjects with Moderate to Severe Asthma
  Condition: Allergic Asthma
  Age: 18-55 years

▪ Non-Invasive Ways to Evaluate Lung Disease After Treatment with Xolair
  Condition: Use of medium-high dose corticosteroids, Moderate-Severe Asthma
  Age: > 12

▪ Efficacy and Safety of Oral Microencapsulated Ragweed Pollen Extract Administered Prior to and During the Ragweed Pollen Season
  Condition: Allergic to Ragweed
  Age: 18-65 years

▪ 26 Week Efficacy, Safety, and Tolerability Study of Indacaterol in Patients with Chronic Obstructive Pulmonary Disease (COPD)
  Condition: COPD
  Age: ≥ 40 years
  Smoking: ≥ 20 years

▪ Safety, Efficacy and Pharmacokinetics of Adalimumab (Anti-TNF Therapy) in Subjects with Refractory Asthma
  Condition: Refractory Asthma
  Age: 18-65 years

▪ Efficacy, Safety and Tolerability of a Ragweed MATA MPL
  Condition: Seasonal Allergic Rhinitis
  Age: 18-59 years

▪ 26 Week Study to Evaluate the Effect of Xolair on Improving Tolerability of Immunotherapy in Patients with Moderate to Severe Persistent Allergic Asthma
  Condition: Persistent Allergic Asthma
  Use of inhaled corticosteroids
  Age: 18-55 years

▪ Short-term Effects of Oral Corticosteroids on CTX (C-Terminal Telopeptides)
  Condition: Steroid Naive Normal
Age: 25-40 years

- **The Effects of Xolair on the Inhibition of Leukotriene and Cytokine (Il-4 and I:-13) Release from Blood Basophils**
  Condition: Seasonal Allergic Rhinitis
  Age: 19-50 years

- **Exhaled Breath Condensate and Nitric Oxide: Non-Invasive Evaluation of Lung Disease after Treatment with Xolair**
  Condition: Allergic Asthma
  Age: ≥ 12 years

- **The Effect of Roflumilast In-Vitro on Basophil, Histamine and Leukotiene, IL-4 and IL-13 Release**
  Condition: Moderate-Severe Allergic Asthma
  Age: ≥ 12 years